P-gp overexpression has been observed in a high percentage of patients following treatment with specific drug combinations commonly used in MM therapy, especially with regimens like doxorubicin/vincristine and VAD (90–100%), clinically hindering drug efficacy and contributing to treatment failure [47]. Here, PGP is linked to Miyoshi myopathy.